WO2002042445A3 - Differentiated cells suitable for human therapy - Google Patents

Differentiated cells suitable for human therapy Download PDF

Info

Publication number
WO2002042445A3
WO2002042445A3 PCT/US2001/044309 US0144309W WO0242445A3 WO 2002042445 A3 WO2002042445 A3 WO 2002042445A3 US 0144309 W US0144309 W US 0144309W WO 0242445 A3 WO0242445 A3 WO 0242445A3
Authority
WO
WIPO (PCT)
Prior art keywords
cell
cells
population
expression
effector
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2001/044309
Other languages
French (fr)
Other versions
WO2002042445A2 (en
Inventor
Joseph D Gold
Jane S Lebrowski
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Geron Corp
Original Assignee
Geron Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to JP2002545150A priority Critical patent/JP2004523217A/en
Priority to ES01986488.3T priority patent/ES2544942T3/en
Priority to AU3768102A priority patent/AU3768102A/en
Priority to KR10-2003-7007100A priority patent/KR20030081334A/en
Priority to GB0313389A priority patent/GB2386120B/en
Priority to IL15569501A priority patent/IL155695A0/en
Priority to AU2002237681A priority patent/AU2002237681B2/en
Priority to CA 2434760 priority patent/CA2434760C/en
Application filed by Geron Corp filed Critical Geron Corp
Priority to EP01986488.3A priority patent/EP1337632B1/en
Priority to US10/141,220 priority patent/US20030040111A1/en
Publication of WO2002042445A2 publication Critical patent/WO2002042445A2/en
Publication of WO2002042445A3 publication Critical patent/WO2002042445A3/en
Priority to IL155695A priority patent/IL155695A/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C12N5/12—Fused cells, e.g. hybridomas
    • C12N5/16—Animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0603—Embryonic cells ; Embryoid bodies
    • C12N5/0606—Pluripotent embryonic cells, e.g. embryonic stem cells [ES]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/13—Coculture with; Conditioned medium produced by connective tissue cells; generic mesenchyme cells, e.g. so-called "embryonic fibroblasts"
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Cell Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Molecular Biology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

This invention provides a system for producing differentiated cells from a stem cell population for use wherever a relatively homogenous cell population is desirable. The cells contain an effector gene under control of a transcriptional control element (such as the TERT promoter) that causes the gene to be expressed in relatively undifferentiated cells in the population. Expression of the effector gene results in depletion of undifferentiated cells, or expression of a marker that can be used to remove them later. Suitable effector sequences encode a toxin, a protein that induces apoptosis, a cell-surface antigen, or an enzyme (such as thymidine kinase) that converts a prodrug into a substance that is lethal to the cell. The differentiated cell populations produced according to this disclosure are suitable for use in tissue regeneration, and non-therapeutic applications such as drug screening.
PCT/US2001/044309 2000-11-27 2001-11-26 Differentiated cells suitable for human therapy Ceased WO2002042445A2 (en)

Priority Applications (11)

Application Number Priority Date Filing Date Title
AU2002237681A AU2002237681B2 (en) 2000-11-27 2001-11-26 Differentiated cells suitable for human therapy
AU3768102A AU3768102A (en) 2000-11-27 2001-11-26 Differentiated cells suitable for human therapy
KR10-2003-7007100A KR20030081334A (en) 2000-11-27 2001-11-26 Differentiated cells suitable for human therapy
GB0313389A GB2386120B (en) 2000-11-27 2001-11-26 Differentiated cells suitable for human therapy
IL15569501A IL155695A0 (en) 2000-11-27 2001-11-26 Differentiated cells suitable for human therapy
CA 2434760 CA2434760C (en) 2000-11-27 2001-11-26 Differentiated cells suitable for human therapy
EP01986488.3A EP1337632B1 (en) 2000-11-27 2001-11-26 Differentiated cells suitable for human therapy
JP2002545150A JP2004523217A (en) 2000-11-27 2001-11-26 Differentiated cells suitable for human therapy
ES01986488.3T ES2544942T3 (en) 2000-11-27 2001-11-26 Differentiated cells suitable for human treatment
US10/141,220 US20030040111A1 (en) 2000-11-27 2002-05-07 Differentiated cells suitable for human therapy
IL155695A IL155695A (en) 2000-11-27 2003-04-30 Differentiated cells suitable for human therapy

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US25344300P 2000-11-27 2000-11-27
US25335700P 2000-11-27 2000-11-27
US60/253,443 2000-11-27
US60/253,357 2000-11-27
US09/783,203 2001-02-13
US09/783,203 US6576464B2 (en) 2000-11-27 2001-02-13 Methods for providing differentiated stem cells

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US10/141,220 Continuation US20030040111A1 (en) 2000-11-27 2002-05-07 Differentiated cells suitable for human therapy

Publications (2)

Publication Number Publication Date
WO2002042445A2 WO2002042445A2 (en) 2002-05-30
WO2002042445A3 true WO2002042445A3 (en) 2003-01-16

Family

ID=27400669

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/044309 Ceased WO2002042445A2 (en) 2000-11-27 2001-11-26 Differentiated cells suitable for human therapy

Country Status (11)

Country Link
US (4) US6576464B2 (en)
EP (1) EP1337632B1 (en)
JP (1) JP2004523217A (en)
KR (1) KR20030081334A (en)
CN (2) CN101928692A (en)
AU (2) AU3768102A (en)
CA (1) CA2434760C (en)
ES (1) ES2544942T3 (en)
GB (1) GB2386120B (en)
IL (2) IL155695A0 (en)
WO (1) WO2002042445A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8426198B2 (en) 2000-11-27 2013-04-23 Geron Corporation In vitro differentiated cell and human embryonic stem cell population

Families Citing this family (97)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7351578B2 (en) 1999-12-10 2008-04-01 Invitrogen Corp. Use of multiple recombination sites with unique specificity in recombinational cloning
US7410798B2 (en) 2001-01-10 2008-08-12 Geron Corporation Culture system for rapid expansion of human embryonic stem cells
WO2001029206A1 (en) * 1999-10-15 2001-04-26 Advanced Cell Technology, Inc. Methods of producing differentiated progenitor cells and lineage-defective embryonic stem cells
US7198924B2 (en) 2000-12-11 2007-04-03 Invitrogen Corporation Methods and compositions for synthesis of nucleic acid molecules using multiple recognition sites
US6921665B2 (en) * 2000-11-27 2005-07-26 Roslin Institute (Edinburgh) Selective antibody targeting of undifferentiated stem cells
US20030104426A1 (en) * 2001-06-18 2003-06-05 Linsley Peter S. Signature genes in chronic myelogenous leukemia
WO2003034985A2 (en) * 2001-10-22 2003-05-01 University Of Rochester Telomerase interference
IL162130A0 (en) 2001-12-07 2005-11-20 Robarts Res Inst Hematopoietic cells from human embryonic stem cells
US7595043B2 (en) 2001-12-07 2009-09-29 Cytori Therapeutics, Inc. Method for processing and using adipose-derived stem cells
US20050095228A1 (en) 2001-12-07 2005-05-05 Fraser John K. Methods of using regenerative cells in the treatment of peripheral vascular disease and related disorders
KR100930139B1 (en) * 2001-12-07 2009-12-07 사이토리 테라퓨틱스, 인크. Systems and methods for treating patients with treated lipoasperate cells
US7651684B2 (en) 2001-12-07 2010-01-26 Cytori Therapeutics, Inc. Methods of using adipose tissue-derived cells in augmenting autologous fat transfer
US20050048035A1 (en) 2001-12-07 2005-03-03 Fraser John K. Methods of using regenerative cells in the treatment of stroke and related diseases and disorders
US7585670B2 (en) 2001-12-07 2009-09-08 Cytori Therapeutics, Inc. Automated methods for isolating and using clinically safe adipose derived regenerative cells
US7771716B2 (en) 2001-12-07 2010-08-10 Cytori Therapeutics, Inc. Methods of using regenerative cells in the treatment of musculoskeletal disorders
US8404229B2 (en) 2001-12-07 2013-03-26 Cytori Therapeutics, Inc. Methods of using adipose derived stem cells to treat acute tubular necrosis
US7514075B2 (en) 2001-12-07 2009-04-07 Cytori Therapeutics, Inc. Systems and methods for separating and concentrating adipose derived stem cells from tissue
US9597395B2 (en) * 2001-12-07 2017-03-21 Cytori Therapeutics, Inc. Methods of using adipose tissue-derived cells in the treatment of cardiovascular conditions
US20030134422A1 (en) * 2002-01-16 2003-07-17 Sayre Chauncey Bigelow Stem cell maturation for all tissue lines
US20050170506A1 (en) * 2002-01-16 2005-08-04 Primegen Biotech Llc Therapeutic reprogramming, hybrid stem cells and maturation
US20050090004A1 (en) * 2003-01-16 2005-04-28 Sayre Chauncey B. Stem cell maturation for all tissue lines
EP1472340A4 (en) * 2002-02-05 2006-11-08 Rappaport Family Inst For Res STRAIN CELLS SELECTED FOR TELOMERASEPROMOTORACTIVITY, CELL-LINKED
US7498171B2 (en) * 2002-04-12 2009-03-03 Anthrogenesis Corporation Modulation of stem and progenitor cell differentiation, assays, and uses thereof
CN1668733A (en) * 2002-05-30 2005-09-14 细胞基因公司 Methods of Regulating Cell Differentiation and Treating Myelodysplasia and Myelodysplastic Syndrome Using JNK or MKK Inhibitors
US7285415B2 (en) 2002-07-11 2007-10-23 The Regents Of The University Of California Oligodendrocytes derived from human embryonic stem cells for remyelination and treatment of spinal cord injury
US20050265983A1 (en) * 2002-11-17 2005-12-01 Eldad Melamed Methods, nucleic acid constructs and cells for treating neurodegenerative disorders
US20050014116A1 (en) * 2002-11-27 2005-01-20 Reid Gregory S. Testing information comprehension of contact center users
US20040214324A1 (en) * 2002-12-09 2004-10-28 Ole Isacson Dopaminergic neurons differentiated from embryonic cells for treating neurodegenerative diseases
AU2003303071B2 (en) 2002-12-16 2009-04-23 Technion Research & Development Foundation Ltd. Methods of preparing feeder cells-free, xeno-free human embryonic stem cells and stem cell cultures prepared using same
US20060211111A1 (en) * 2002-12-18 2006-09-21 Maisam Mitalipova Compositions and methods for neural cell production and stabilization
US7153650B2 (en) 2003-03-13 2006-12-26 Geron Corporation Marker system for preparing and characterizing high-quality human embryonic stem cells
US20060281136A1 (en) * 2003-05-20 2006-12-14 Shinichi Nishikawa Preparation of endodermal stem cells
EP2578676A1 (en) 2003-06-20 2013-04-10 Axiogenesis Ag Tissue modeling in multi- or pluripotent cell systems
AR046076A1 (en) * 2003-07-18 2005-11-23 Otsuka Pharma Co Ltd PROCEDURE FOR OBTAINING A HOMOGENOUS POPULATION OF OLIGODENDROCIT PRECURSOR CELLS AND OBTAINED POPULATION
US20050054100A1 (en) * 2003-09-08 2005-03-10 Rennard Stephen I. Methods for fibroblast differentiation
WO2005054438A2 (en) 2003-12-01 2005-06-16 Invitrogen Corporation Nucleic acid molecules containing recombination sites and methods of using the same
EP2929782A1 (en) * 2004-01-23 2015-10-14 Ocata Therapeutics, Inc. Improved modalities for the treatment of degenerative diseases of the retina
US7794704B2 (en) 2004-01-23 2010-09-14 Advanced Cell Technology, Inc. Methods for producing enriched populations of human retinal pigment epithelium cells for treatment of retinal degeneration
WO2005079849A2 (en) * 2004-02-25 2005-09-01 Zgene A/S Compounds for enhanced cancer therapy
US20050277124A1 (en) * 2004-06-10 2005-12-15 White Steven M Cardiac conduction system cells and uses thereof
WO2006014159A2 (en) * 2004-07-01 2006-02-09 Macropore Biosurgery Inc. Methods of using regenerative cells in the treatment of musculoskeletal disorders
WO2006044204A2 (en) * 2004-10-05 2006-04-27 University Of Georgia Research Foundation, Inc. Neuronal progenitors from feeder-free human embryonic stem cell culture
US20060148080A1 (en) * 2004-12-30 2006-07-06 Paul Diamond Methods for supporting and producing human cells and tissues in non-human mammal hosts
US20060147429A1 (en) * 2004-12-30 2006-07-06 Paul Diamond Facilitated cellular reconstitution of organs and tissues
JP5006312B2 (en) * 2005-05-27 2012-08-22 エイジェンシー フォー サイエンス， テクノロジー アンド リサーチ Methods for delivering nucleic acid molecules to embryonic stem cells using baculovirus vectors
EP2465924A3 (en) 2005-06-16 2013-01-02 Ramot at Tel-Aviv University Ltd. Isolated cells and populations comprising same for the treament of cns diseases
JP5560391B2 (en) 2005-06-22 2014-07-23 アステリアス バイオセラピューティクス インコーポレイテッド Suspension culture method of human embryonic stem cells
EP1962719A4 (en) 2005-08-29 2011-05-04 Technion Res And Dev Of Foundation Ltd CULTURE MEDIA OF STEM CELLS
CN1966080B (en) * 2005-11-17 2011-06-08 李凌松 Neural stem cell injection for treating senile dementia and Parkinson's disease
US20100021434A1 (en) * 2005-12-08 2010-01-28 Ramot At Tel Aviv University Ltd. Isolated Oligodendrocyte-Like Cells and Populations Comprising Same for the Treatment of CNS Diseases
WO2007139551A1 (en) * 2006-05-30 2007-12-06 Cytori Therapeutics, Inc. Systems and methods for manipulation of regenerative cells from adipose tissue
WO2008013863A2 (en) * 2006-07-26 2008-01-31 Cytori Therapeutics, Inc. Generation of adipose tissue and adipocytes
DK3441459T3 (en) 2006-08-02 2021-06-07 Technion Res & Dev Foundation PROCEDURES FOR EXPANSION OF EMBRYONAL STEM CELLS IN A SUSPENSION CULTURE
US20080081370A1 (en) * 2006-09-28 2008-04-03 Peiman Hematti Directed differentiation of human embryonic stem cells into mesenchymal/stromal cells
DK2209888T3 (en) 2007-10-12 2020-01-20 Astellas Inst For Regenerative Medicine IMPROVED PROCEDURES FOR PREPARING RPE CELLS AND COMPOSITIONS OF RPE CELLS
US8501474B2 (en) * 2007-10-15 2013-08-06 Technion Research & Development Foundation Limited Methods of generating embryoid bodies and uses of same
EP2620493B1 (en) 2008-05-28 2019-03-27 Ramot at Tel Aviv University Ltd. Mesenchymal stem cells for the treatment of CNS diseases
WO2010021993A1 (en) * 2008-08-19 2010-02-25 Cytori Therapeutics, Inc. Methods of using adipose tissue-derived cells in the treatment of the lymphatic system and malignant disease
WO2010114136A1 (en) * 2009-03-30 2010-10-07 第一三共株式会社 Method for inducing cell death in pluripotent stem cells and differentiated cells other than cardiac myocytes
AU2010242780B2 (en) * 2009-05-01 2016-04-21 Puregraft Llc Systems, methods and compositions for optimizing tissue and cell enriched grafts
CN102803472B (en) * 2009-06-25 2014-04-23 吉隆公司 Progeny cells differentiated from pluripotent stem cells with foreign phenotype removed
US9018010B2 (en) 2009-11-12 2015-04-28 Technion Research & Development Foundation Limited Culture media, cell cultures and methods of culturing pluripotent stem cells in an undifferentiated state
IL281453B (en) 2009-11-17 2022-07-01 Astellas Inst For Regenerative Medicine Methods of producing human rpe cells and pharmaceutical preparations of human rpe cells
US9029145B2 (en) 2010-04-08 2015-05-12 The University Court Of The University Of Edinburgh Chondrogenic progenitor cells, protocol for derivation of cells and uses thereof
WO2012048276A2 (en) 2010-10-08 2012-04-12 Caridianbct, Inc. Customizable methods and systems of growing and harvesting cells in a hollow fiber bioreactor system
JP6037393B2 (en) * 2011-03-29 2016-12-07 国立大学法人 鹿児島大学 Methods for removing tumorigenic cells in stem cells
US10745468B2 (en) 2011-12-22 2020-08-18 Kota Biotherapeutics, Llc Compositions and methods for modified B cells expressing reassigned biological agents
US10233424B2 (en) 2011-12-22 2019-03-19 Elwha Llc Compositions and methods including cytotoxic B lymphocyte cell line expressing exogenous membrane immunoglobulin different from secreted immunoglobulin
US9175072B2 (en) 2011-12-22 2015-11-03 Elwha Llc Compositions and methods including recombinant B lymphocyte cell line including an exogenously incorporated nucleic acid expressing an exogenous membrane immunoglobulin reactive to a first antigen and including an endogenous gene expressing an endogenous secreted immunoglobulin reactive to a second antigen
US8962315B2 (en) 2011-12-22 2015-02-24 Elwha Llc Compositions and methods including recombinant B lymphocyte cell line including at least one endogenous gene expressing at least one endogenous membrane immunoglobulin reactive to a first antigen and including at least one exogenously incorporated nucleic acid expressing at least one exogenous secreted immunoglobulin reactive to a second antigen
WO2013134015A2 (en) 2012-03-05 2013-09-12 Wake Forest University Health Sciences Non-viral episomal suicide construct
CN120796168A (en) 2013-06-11 2025-10-17 哈佛学院校长同事会 SC-beta cells, compositions and methods for producing the same
WO2015073913A1 (en) 2013-11-16 2015-05-21 Terumo Bct, Inc. Expanding cells in a bioreactor
WO2015148704A1 (en) 2014-03-25 2015-10-01 Terumo Bct, Inc. Passive replacement of media
US20170114323A1 (en) 2014-06-19 2017-04-27 Whitehead Institute For Biomedical Research Uses of kinase inhibitors for inducing and maintaining pluripotency
EP3198006B1 (en) 2014-09-26 2021-03-24 Terumo BCT, Inc. Scheduled feed
WO2016100898A1 (en) 2014-12-18 2016-06-23 President And Fellows Of Harvard College Serum-free in vitro directed differentiation protocol for generating stem cell-derived b cells and uses thereof
CN107614678B (en) 2014-12-18 2021-04-30 哈佛学院校长同事会 Method for producing stem cell-derived beta cells and method for using same
EP3234110B1 (en) 2014-12-18 2024-02-28 President and Fellows of Harvard College METHODS FOR GENERATING STEM CELL-DERIVED ß CELLS AND USES THEREOF
WO2017004592A1 (en) 2015-07-02 2017-01-05 Terumo Bct, Inc. Cell growth with mechanical stimuli
US11965175B2 (en) 2016-05-25 2024-04-23 Terumo Bct, Inc. Cell expansion
US11104874B2 (en) 2016-06-07 2021-08-31 Terumo Bct, Inc. Coating a bioreactor
US11685883B2 (en) 2016-06-07 2023-06-27 Terumo Bct, Inc. Methods and systems for coating a cell growth surface
CN109563482A (en) 2016-06-10 2019-04-02 埃尔瓦有限公司 Containing expression different from the composition and method of the bone-marrow-derived lymphocyte system of immunoglobulin,exocrine and the membrane immunoglobulin of cell dissolution function
KR102106895B1 (en) * 2017-02-16 2020-05-07 고려대학교 산학협력단 Composition for preventing or treating bone disease having excellent bone regeneration ability
US12234441B2 (en) 2017-03-31 2025-02-25 Terumo Bct, Inc. Cell expansion
CN117247899A (en) 2017-03-31 2023-12-19 泰尔茂比司特公司 cell expansion
US11624046B2 (en) 2017-03-31 2023-04-11 Terumo Bct, Inc. Cell expansion
JP2020535834A (en) 2017-10-03 2020-12-10 エスディーエフ バイオファーマ インコーポレイテッド Treatment of diabetes with genetically modified beta cells
EP3710021A4 (en) 2017-11-15 2021-08-11 Semma Therapeutics, Inc. COMPOSITIONS FOR THE MANUFACTURE OF ISLAND CELLS AND METHODS OF USE
WO2020033879A1 (en) 2018-08-10 2020-02-13 Semma Therapeutics, Inc. Stem cell derived islet differentiation
EP4314244B1 (en) 2021-03-23 2025-07-23 Terumo BCT, Inc. Cell capture and expansion
US12371667B2 (en) 2021-05-13 2025-07-29 Washington University Enhanced methods for inducing and maintaining naive human pluripotent stem cells
US12209689B2 (en) 2022-02-28 2025-01-28 Terumo Kabushiki Kaisha Multiple-tube pinch valve assembly
USD1099116S1 (en) 2022-09-01 2025-10-21 Terumo Bct, Inc. Display screen or portion thereof with a graphical user interface for displaying cell culture process steps and measurements of an associated bioreactor device
CN119184024A (en) * 2024-08-27 2024-12-27 南京农业大学 Method for increasing animal early embryo field planting quantity and promoting embryo development
CN119709646A (en) * 2024-09-14 2025-03-28 青岛阿尔泰基因工程有限公司 Lentivirus for treating craniopharyngeal tube tumor and preparation method and application thereof

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999019469A1 (en) * 1997-10-09 1999-04-22 Biotransplant, Inc. Porcine stem cells comprising a marker under an oct-4 promoter
WO1999020741A1 (en) * 1997-10-23 1999-04-29 Geron Corporation Methods and materials for the growth of primate-derived primordial stem cells
WO1999045100A1 (en) * 1998-03-02 1999-09-10 University Of Massachusetts, A Public Institution Of Higher Education Of The Commonwealth Of Massachusetts, As Represented By Its Amherst Campus Embryonic or stem-like cell lines produced by cross-species nuclear transplantation
WO2001088104A2 (en) * 2000-05-17 2001-11-22 Geron Corporation Neural progenitor cell populations

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4959313A (en) 1987-06-22 1990-09-25 The Jackson Laboratory Cellular enhancer for expressing genes in undifferentiated stem cells
US5082670A (en) 1988-12-15 1992-01-21 The Regents Of The University Of California Method of grafting genetically modified cells to treat defects, disease or damage or the central nervous system
US5068191A (en) * 1989-08-31 1991-11-26 The Biomembrane Institute Purified histo-blood group a glycosyltransferase and antibodies thereto
US5061620A (en) 1990-03-30 1991-10-29 Systemix, Inc. Human hematopoietic stem cell
US5851832A (en) 1991-07-08 1998-12-22 Neurospheres, Ltd. In vitro growth and proliferation of multipotent neural stem cells and their progeny
US5639613A (en) 1992-05-13 1997-06-17 Board Of Regents, University Of Texas System Methods for cancer diagnosis and prognosis
NZ256154A (en) 1992-07-27 1997-02-24 California Inst Of Techn Production of mammalian multipotent neural stem cells, antibodies
US5672499A (en) 1992-07-27 1997-09-30 California Institute Of Technology Immoralized neural crest stem cells and methods of making
US5766948A (en) 1993-01-06 1998-06-16 The Regents Of The University Of California Method for production of neuroblasts
GB9308271D0 (en) * 1993-04-21 1993-06-02 Univ Edinburgh Method of isolating and/or enriching and/or selectively propagating pluripotential animal cells and animals for use in said method
US5523226A (en) 1993-05-14 1996-06-04 Biotechnology Research And Development Corp. Transgenic swine compositions and methods
US5631236A (en) 1993-08-26 1997-05-20 Baylor College Of Medicine Gene therapy for solid tumors, using a DNA sequence encoding HSV-Tk or VZV-Tk
US5409813A (en) * 1993-09-30 1995-04-25 Systemix, Inc. Method for mammalian cell separation from a mixture of cell populations
US6015671A (en) * 1995-06-07 2000-01-18 Indiana University Foundation Myocardial grafts and cellular compositions
US6204431B1 (en) * 1994-03-09 2001-03-20 Abbott Laboratories Transgenic non-human mammals expressing heterologous glycosyltransferase DNA sequences produce oligosaccharides and glycoproteins in their milk
US5489304A (en) 1994-04-19 1996-02-06 Brigham & Women's Hospital Method of skin regeneration using a collagen-glycosaminoglycan matrix and cultured epithelial autograft
US5639618A (en) 1994-05-13 1997-06-17 Plurion, Inc. Method of isolating a lineage specific stem cell in vitro
GB9417831D0 (en) 1994-09-05 1994-10-26 Biotech & Biolog Scien Res Biological manipulation
US5843780A (en) 1995-01-20 1998-12-01 Wisconsin Alumni Research Foundation Primate embryonic stem cells
US5736396A (en) 1995-01-24 1998-04-07 Case Western Reserve University Lineage-directed induction of human mesenchymal stem cell differentiation
GB9505663D0 (en) 1995-03-21 1995-05-10 Stringer Bradley M J Genetically modified neural cells
US6117985A (en) * 1995-06-16 2000-09-12 Stemcell Technologies Inc. Antibody compositions for preparing enriched cell preparations
GB9526509D0 (en) 1995-12-23 1996-02-28 Univ Dundee Gene control
GB9807935D0 (en) 1998-04-14 1998-06-10 Univ Edinburgh Lineage specific cells and progenitor cells
WO1997032025A1 (en) 1996-03-01 1997-09-04 Regents Of The University Of Minnesota Method for selective engraftment of drug-resistant hematopoietic stem cells
AU741438B2 (en) 1996-08-26 2001-11-29 Hemasure, Inc. Method for removing tumor cells from tumor cell-contaminated stem cell products
IL129222A0 (en) 1996-10-01 2000-02-17 Geron Corp Telomerase reverse transcriptase
GB9621383D0 (en) 1996-10-14 1996-12-04 Roslin Inst Edinburgh Transgene expression
CA2279542A1 (en) 1997-02-05 1998-08-06 The General Hospital Corporation Tolerance to natural antibody antigens
WO1998039427A2 (en) 1997-03-06 1998-09-11 University Of Massachusetts Gene therapy using bone marrow transplants transfected with therapeutic genes under the control of tissue-specific promoters
US6090622A (en) 1997-03-31 2000-07-18 The Johns Hopkins School Of Medicine Human embryonic pluripotent germ cells
DE19727962A1 (en) 1997-07-02 1999-01-14 Juergen Hescheler Fluorescent proteins as cell type-specific reporters
WO1999010535A1 (en) 1997-08-22 1999-03-04 Yale University A process to study changes in gene expression in stem cells
US5968829A (en) 1997-09-05 1999-10-19 Cytotherapeutics, Inc. Human CNS neural stem cells
WO1999027076A1 (en) 1997-11-25 1999-06-03 Arc Genomic Research Pluripotent embryonic stem cells and methods of obtaining them
DE19757984A1 (en) 1997-12-24 1999-07-01 Bayer Ag Regulatory DNA sequences from the 5 'region of the gene of the human catalytic telomerase subunit and their diagnostic and therapeutic use
WO2000018885A1 (en) 1998-09-29 2000-04-06 Gamida Cell Ltd. Methods of controlling proliferation and differentiation of stem and progenitor cells
GB9811859D0 (en) 1998-06-02 1998-07-29 Biotech & Biolog Scien Res Biological manipulation
GB9819912D0 (en) 1998-09-11 1998-11-04 Univ Edinburgh Propagation and/or derivation of embryonic stem cells
US7410798B2 (en) * 2001-01-10 2008-08-12 Geron Corporation Culture system for rapid expansion of human embryonic stem cells
US6667176B1 (en) * 2000-01-11 2003-12-23 Geron Corporation cDNA libraries reflecting gene expression during growth and differentiation of human pluripotent stem cells
US6087168A (en) 1999-01-20 2000-07-11 Cedars Sinai Medical Center Conversion of non-neuronal cells into neurons: transdifferentiation of epidermal cells
EP1147181B1 (en) 1999-02-04 2004-05-12 Geron Corporation Replicative virus driven by the promoter for telomerase reverse transcriptase for use in treating cancer
WO2001011011A2 (en) 1999-08-05 2001-02-15 Mcl Llc Multipotent adult stem cells and methods for isolation
US6458589B1 (en) * 2000-04-27 2002-10-01 Geron Corporation Hepatocyte lineage cells derived from pluripotent stem cells
WO2002061033A2 (en) 2000-11-27 2002-08-08 Yissum Research Development Company Of The Hebrew University Of Jerusalem Transfection of human embryonic stem cells
US6576464B2 (en) 2000-11-27 2003-06-10 Geron Corporation Methods for providing differentiated stem cells
US6921665B2 (en) * 2000-11-27 2005-07-26 Roslin Institute (Edinburgh) Selective antibody targeting of undifferentiated stem cells

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999019469A1 (en) * 1997-10-09 1999-04-22 Biotransplant, Inc. Porcine stem cells comprising a marker under an oct-4 promoter
WO1999020741A1 (en) * 1997-10-23 1999-04-29 Geron Corporation Methods and materials for the growth of primate-derived primordial stem cells
WO1999045100A1 (en) * 1998-03-02 1999-09-10 University Of Massachusetts, A Public Institution Of Higher Education Of The Commonwealth Of Massachusetts, As Represented By Its Amherst Campus Embryonic or stem-like cell lines produced by cross-species nuclear transplantation
WO2001088104A2 (en) * 2000-05-17 2001-11-22 Geron Corporation Neural progenitor cell populations

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8426198B2 (en) 2000-11-27 2013-04-23 Geron Corporation In vitro differentiated cell and human embryonic stem cell population

Also Published As

Publication number Publication date
US20130273651A1 (en) 2013-10-17
ES2544942T3 (en) 2015-09-07
CA2434760C (en) 2013-09-24
IL155695A0 (en) 2003-11-23
GB0313389D0 (en) 2003-07-16
EP1337632A2 (en) 2003-08-27
US6576464B2 (en) 2003-06-10
US20060134782A1 (en) 2006-06-22
CA2434760A1 (en) 2002-05-30
AU2002237681B2 (en) 2007-03-22
AU3768102A (en) 2002-06-03
CN101928692A (en) 2010-12-29
EP1337632B1 (en) 2015-05-20
GB2386120B (en) 2005-03-09
WO2002042445A2 (en) 2002-05-30
KR20030081334A (en) 2003-10-17
US9023645B2 (en) 2015-05-05
JP2004523217A (en) 2004-08-05
US20020098582A1 (en) 2002-07-25
US8426198B2 (en) 2013-04-23
IL155695A (en) 2007-10-31
GB2386120A (en) 2003-09-10
US20030040111A1 (en) 2003-02-27
CN1478145A (en) 2004-02-25

Similar Documents

Publication Publication Date Title
WO2002042445A3 (en) Differentiated cells suitable for human therapy
IL117425A0 (en) Receptor activation by gas6
WO2002059277A3 (en) Electroactive materials for stimulation of biological activity of stem cells
AU2001270408A1 (en) Intervertebral disc
HUP0003533A2 (en) Interleukin-18 binding proteins, their preparation and use
WO1998019167A3 (en) Cell stress regulated human mhc class i gene
WO2002016598A3 (en) Nucleic acid and corresponding protein named 158p1h4 useful in the treatment and detection of bladder and other cancers
WO2000029551A3 (en) Cells, culture methods, and their use in autologous transplantation therapy
AU5559499A (en) Identification of the gene causing the mouse scurfy phenotype and its human ortholog
WO1998011234A3 (en) Human protein kinases
AU2826801A (en) Surface modified supporting materials for binding biological materials, method for the production and use thereof
ATE310828T1 (en) IMPLANT AND VECTOR FOR THE TREATMENT OF ACQUIRED DISEASES
AU2001238064A1 (en) 18477, a human protein kinase and uses therefor
AU2001234544A1 (en) Novel human protein kinases and protein kinase-like enzymes
AU3118095A (en) Dna sequences coding for the human proteins tx and ty related to the interleukin-1beta converting enzyme
GB2379446A (en) Cells,culture methods and their uses
WO2000066735A3 (en) Human ion channel proteins
WO2004072263A3 (en) Nucleic acid and corresponding protein named 158p1d7 useful in the treatment and detection of bladder and other cancers
AU2001292310A1 (en) Method of regulating the activity of expression product of gene transferred intoliving body
WO1998024482A3 (en) Use of endothelin conjugates in therapy, new endothelin conjugates, substances containing them, and processes for producing them
WO2002000878A3 (en) Human msp1 mitochondrial dynamin, its msp1-x isoforms, and their therapeutic use
WO2004047758A3 (en) Methods of therapy and diagnosis using targeting of cells that express p2y10
WO2002002771A3 (en) Human sparc-homologous (hsparc-h1) gene and methods and uses thereof
DE60118938D1 (en) A RESISTANCE TO THE ANTIBACTERIAL 4,5-DIHYDROXY-2-CYCLOPENTEN-1-ON (DHCP) DISTRIBUTES THE GENE THAT ENDED PROTEIN AND USES THEREOF
WO2004053061A3 (en) Methods of therapy and diagnosis using targeting of cells that express lax

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 10141220

Country of ref document: US

AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

ENP Entry into the national phase

Ref document number: 0313389

Country of ref document: GB

Kind code of ref document: A

Free format text: PCT FILING DATE = 20011126

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 155695

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 2002237681

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2434760

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 782/CHENP/2003

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 018196470

Country of ref document: CN

Ref document number: 1020037007100

Country of ref document: KR

Ref document number: 2002545150

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2001986488

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2001986488

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 1020037007100

Country of ref document: KR

WWG Wipo information: grant in national office

Ref document number: 2002237681

Country of ref document: AU